On the other hand, when the liver cancers were treated with pCas9D10A-EGFP or pSLAM-HSV1-tk-mCherry-gRNA alone, the tumor progressed significantly, reaching 18.2- (p < 0.01) and 12.1 (p < 0.01)-fold of the treatment group, respectively. This evidence concerns the gene TKT and liver cancer.